Physician profile
Muhammad Naeem
NPI 1245284165
$525.58
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.16 · 2021: $75.05 · 2022: $33.34 · 2023: $180 · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $86.78 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.20 | 2021-2022 | |
| Lilly USA, LLC | $54.55 | 2023-2024 | Mounjaro, Emgality |
| Pfizer INC. | $34.68 | 2022-2023 | |
| Janssen Biotech, INC. | $32.92 | 2023 | Remicade, Simponi, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.44 | 2021 | |
| Astellas Pharma US INC | $19.26 | 2023 | Veozah |
| Novo Nordisk INC | $18.51 | 2024 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $18.32 | 2024 | Xyosted |
| Amgen INC. | $15.22 | 2023 | Repatha |
| Exact Sciences Corporation | $14.28 | 2023 | Cologuard Collection Kit |
| Genzyme Corporation | $14.16 | 2020 | |
| Adamas Pharmaceuticals, INC. | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Naeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.